| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5256630 | F | Antiproliferative activity against human AMO1 cells assessed as inhibition of cell proliferation at 1 uM incubated for 5 days by WST-1 assay | Homo sapiens | 5 | cell-based format | Scientific Literature | ||
| 2. | ALA5256631 | F | Antiproliferative activity against pomalidomide resistant human AMO1 cells assessed as inhibition of cell proliferation at 1 uM incubated for 5 days by WST-1 assay | Homo sapiens | 5 | cell-based format | Scientific Literature | ||
| 3. | ALA4015798 | F | Antiproliferative activity against BCL6 dependent human AMO1 cells after 3 days by CellTiter-Glo assay | Homo sapiens | 18 | cell-based format | Scientific Literature | ||
| 4. | ALA4385934 | F | Antiproliferative activity against Mcl1-sensitive human AMO1 cells assessed as cell growth inhibition measured after 72 hrs by Celltiter-glo luminescence assay | Homo sapiens | 1 | assay format | Scientific Literature | ||
| 5. | ALA4385935 | F | Antitumour activity against Mcl1-sensitive human AMO1 cells xenografted in SCID mouse assessed as tumor growth inhibition at 100 mg/kg, ip administered daily for 14 days measured daily during compound dosing relative to control | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 6. | ALA4385953 | F | Antitumour activity against Mcl1-sensitive human AMO1 cells xenografted in ip dosed SCID mouse assessed as tumor growth inhibition administered daily for 14 days measured daily during compound dosing | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 7. | ALA4677125 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor growth inhibition at 12.5 mg/kg, iv administered weekly for upto week 4 measured post last dose measured on day 10 | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 8. | ALA4677126 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor growth inhibition at 12.5 mg/kg, iv administered daily measured on day 10 | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 9. | ALA4677127 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor regression at 12.5 mg/kg, iv administered for 5 consecutive days and observed upto day 35 post last dose | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 10. | ALA4677128 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor growth inhibition administered intravenously for 5 consecutive days measured post-last dose | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 11. | ALA4677129 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as maximum tumor growth inhibition at 12.5 mg/kg, iv administered for 5 consecutive days measured post-last dose | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 12. | ALA4677130 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as maximum tumor growth inhibition at 3.125 mg/kg, iv administered for 5 consecutive days measured post-last dose | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 13. | ALA4677131 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as maximum tumor growth inhibition at 6.25 mg/kg, iv administered for 5 consecutive days measured post-last dose | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4677162 | F | Antitumor activity against human AMO1 cells xenografted in CB-17 SCID mouse assessed as time to reach tumor volume of 500 mm3 at 6.25 mg/kg, iv administered as bolus dose for 5 consecutive days | Homo sapiens | 5 | organism-based format | Scientific Literature | ||
| 15. | ALA4677163 | F | Antitumor activity against human AMO1 cells xenografted in CB-17 SCID mouse assessed as time to reach tumor volume of 500 mm3 at 12.5 mg/kg, iv administered as bolus dose for 5 consecutive days | Homo sapiens | 4 | organism-based format | Scientific Literature | ||
| 16. | ALA4677164 | F | Antitumor activity against human AMO1 cells xenografted in CB-17 SCID mouse assessed as time to reach tumor volume of 500 mm3 at 25 mg/kg, iv administered as bolus dose for 5 consecutive days | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 17. | ALA4677165 | F | Antitumor activity against human AMO1 cells xenografted in CB-17 SCID mouse assessed as time to reach tumor volume of 500 mm3 at 50 mg/kg, iv administered as bolus dose for 5 consecutive days | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 18. | ALA4677166 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor growth suppression at 50 mg/kg, iv administered for 5 consecutive days measured after 5 weeks | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4677167 | F | Antitumor activity against human AMO1 xenografted in CB-17 SCID mouse assessed as tumor growth suppression at 25 mg/kg, iv administered for 5 consecutive days and measured post-last dose | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA4677168 | F | Antitumor activity against human AMO1 cells xenografted in CB-17 SCID mouse assessed as maximum tumor growth inhibition at 6.25 mg/kg, iv administered as bolus dose for 5 consecutive days measured on day 4 relative to control | Homo sapiens | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!